Literature DB >> 10952692

Selective monoamine oxidase subtype inhibition and striatal extracellular dopamine in the guinea-pig.

T Ilani1, I Lamensdorf, J P Finberg.   

Abstract

Striatal microdialysate levels of dopamine (DA) in conscious guinea-pigs were measured following acute (1 day) and chronic (21 days) treatment with deprenyl (2 and 0.25 mg kg(-1) s.c., respectively) or clorgyline (4 and 1 mg kg(-1) s.c., respectively), as well as by combination treatment using the same doses of the two inhibitors. These treatments caused selective inhibition of monoamine oxidase type B (MAO-B) or monoamine oxidase type A (MAO-A) respectively. Neither acute nor chronic treatments with deprenyl or clorgyline increased basal or KCl-induced DA levels. Acute and chronic clorgyline treatments were accompanied by significant reductions in striatal microdialysate 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA). On the other hand, both acute and chronic deprenyl treatments were accompanied by significant increases in microdialysate HVA with no effect on DOPAC levels. Acute or chronic combined treatment with clorgyline and deprenyl increased tissue but not microdialysate DA levels. The combination treatment given chronically also reduced KCl-induced DA release but enhanced amphetamine-induced DA release. Microdialysate DA levels increased to a smaller extent in guinea-pig than in rat following local striatal infusion of GBR-12909 (100 microM). The difference between guinea-pigs and rats in the response to GBR-12909, could be the result of a lower dopaminergic innervation and/or density of DA transporter. This difference may explain why striatal microdialysate DA levels increased following chronic deprenyl treatment in the rat but not in the guinea-pig.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10952692      PMCID: PMC1572260          DOI: 10.1038/sj.bjp.0703493

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  26 in total

1.  Inhibition of monoamine oxidase-B by (-)-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum.

Authors:  I A Paterson; A V Juorio; M D Berry; M Y Zhu
Journal:  J Pharmacol Exp Ther       Date:  1991-09       Impact factor: 4.030

Review 2.  Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action.

Authors:  C W Olanow
Journal:  J Neural Transm Suppl       Date:  1996

3.  Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter.

Authors:  S R Sesack; V A Hawrylak; C Matus; M A Guido; A I Levey
Journal:  J Neurosci       Date:  1998-04-01       Impact factor: 6.167

4.  Electrophysiological effects of monoamine oxidase inhibition on rat midbrain dopaminergic neurones: an in vitro study.

Authors:  N B Mercuri; A Bonci; A Siniscalchi; A Stefani; P Calabresi; G Bernardi
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

5.  Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.

Authors:  I Lamensdorf; M B Youdim; J P Finberg
Journal:  J Neurochem       Date:  1996-10       Impact factor: 5.372

6.  Effect of L-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake.

Authors:  J Fang; P H Yu
Journal:  Neuropharmacology       Date:  1994-06       Impact factor: 5.250

7.  Selegiline as initial treatment in de novo parkinsonian patients.

Authors:  V V Myllylä; K A Sotaniemi; J A Vuorinen; E H Heinonen
Journal:  Neurology       Date:  1992-02       Impact factor: 9.910

8.  The effect of inhibition of synthesis, release, metabolism and uptake on the microdialysis extraction fraction of dopamine.

Authors:  A D Smith; J B Justice
Journal:  J Neurosci Methods       Date:  1994-09       Impact factor: 2.390

9.  (-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons.

Authors:  J Knoll; I Miklya; B Knoll; R Markó; K Kelemen
Journal:  Life Sci       Date:  1996       Impact factor: 5.037

10.  The effects of administration of monoamine oxidase-B inhibitors on rat striatal neurone responses to dopamine.

Authors:  M D Berry; E Scarr; M Y Zhu; I A Paterson; A V Juorio
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

View more
  5 in total

1.  3-Iodothyronamine: a modulator of the hypothalamus-pancreas-thyroid axes in mice.

Authors:  Maria Elena Manni; Gaetano De Siena; Alessandro Saba; Maja Marchini; Ilaria Dicembrini; Elisabetta Bigagli; Lorenzo Cinci; Maura Lodovici; Grazia Chiellini; Riccardo Zucchi; Laura Raimondi
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

2.  Modification of L-DOPA pharmacological activity by MAO inhibitors.

Authors:  J P M Finberg; O Sader-Mazbar
Journal:  J Neural Transm (Vienna)       Date:  2007-04-10       Impact factor: 3.575

3.  Characterization of Dopaminergic System in the Striatum of Young Adult Park2-/- Knockout Rats.

Authors:  Jickssa M Gemechu; Akhil Sharma; Dongyue Yu; Yuran Xie; Olivia M Merkel; Anna Moszczynska
Journal:  Sci Rep       Date:  2018-01-24       Impact factor: 4.379

4.  Dopamine and serotonin transporter availability during acute alcohol withdrawal: effects of comorbid tobacco smoking.

Authors:  Kelly P Cosgrove; Erica Krantzler; Erin B Frohlich; Stephanie Stiklus; Brian Pittman; Gilles D Tamagnan; Ronald M Baldwin; Frederic Bois; John P Seibyl; John H Krystal; Stephanie S O'Malley; Julie K Staley
Journal:  Neuropsychopharmacology       Date:  2009-05-13       Impact factor: 7.853

Review 5.  Investigational agents in the treatment of Parkinson's disease: focus on safinamide.

Authors:  Naveed M Malek; Donald G Grosset
Journal:  J Exp Pharmacol       Date:  2012-08-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.